title: [Tuberculosis: relevance of isoniazid dosage in prevention of liver side effects].
abstract: OBJECTIVE
  Several recent studies have established a correlation between NAT2 polymorphism and hepatotoxicity induced by isoniazid. The objective of this work was to assess the place of isoniazid dosage, marker of acetylation phenotype, in clinical practice in the department of Haute-Garonne.
  
  
  METHODS
  Data from reportable disease of tuberculosis and the results of isoniazid dosage performed at the pharmacokinetics and clinical toxicology laboratory were used during the period 2009-2012.
  
  
  RESULTS
  The current practice of dosage is far from being systematical: only 3.9% of patients who developed tuberculosis have benefited from isoniazid dosage. The isoniazid initial posology was adapted to the acetylation capacity for only 33.3% of patients.
  
  
  CONCLUSIONS
  A decision tree was realized and used to identify populations (low metabolism) liable to benefit from isoniazid dosage.
authors.affiliation: Laboratoire de pharmacocinétique et toxicologie clinique, Hôpital Purpan, Institut fédératif de biologie (IFB), Toulouse, France.
authors.forename: Lucie
authors.initials: L
authors.lastname: Negri
authors.affiliation: Centre de lutte antituberculeuse, Hôpital Joseph Ducuing, Toulouse, France.
authors.forename: Jean
authors.initials: J
authors.lastname: Le Grusse
authors.affiliation: Laboratoire de pharmacocinétique et toxicologie clinique, Hôpital Purpan, Institut fédératif de biologie (IFB), Toulouse, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Séraissol
authors.affiliation: Laboratoire de pharmacocinétique et toxicologie clinique, Hôpital Purpan, Institut fédératif de biologie (IFB), Toulouse, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Lavit
authors.affiliation: Laboratoire de pharmacocinétique et toxicologie clinique, Hôpital Purpan, Institut fédératif de biologie (IFB), Toulouse, France.
authors.forename: Georges
authors.initials: G
authors.lastname: Houin
authors.affiliation: Laboratoire de pharmacocinétique et toxicologie clinique, Hôpital Purpan, Institut fédératif de biologie (IFB), Toulouse, France - EA4553, Laboratoire de pharmacocinétique, Institut Claudius Regaud, Toulouse, France.
authors.forename: Peggy
authors.initials: P
authors.lastname: Gandia
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001191:Arylamine N-Acetyltransferase / Q000235:genetics; D056486:Chemical and Drug Induced Liver Injury / Q000235:genetics / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000009:adverse effects; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human; D007538:Isoniazid